bio-techne
TOCRIS

Print Date: Jan 23rd 2024

Certificate of Analysis

www.tocris.com

Product Name: **BMS 303141** **Catalog No.: 4609** **Batch No.: 3**

CAS Number: 943962-47-8

IUPAC Name: 3,5-Dichloro-2-hydroxy-*N*-(4-methoxy[1,1'-biphenyl]-3-yl)-benzenesulfonamide

1. PHYSICAL AND CHEMICAL PROPERTIES

Batch Molecular Formula: $C_{19}H_{15}Cl_2NO_4S$

Batch Molecular Weight: 424.3

Physical Appearance: Off-white solid

Solubility: DMSO to 10 mM
ethanol to 50 mM

Storage: Store at -20°C

Batch Molecular Structure:



2. ANALYTICAL DATA

HPLC: Shows 100.0% purity

^{1}H NMR: Consistent with structure

Mass Spectrum: Consistent with structure

Microanalysis:

	Carbon	Hydrogen	Nitrogen
Theoretical	53.78	3.56	3.3
Found	53.01	3.51	3.26

bio-techne.com
info@bio-techne.com
techsupport@bio-techne.com

North America
Tel: (800) 343 7475

China
info.cn@bio-techne.com
Tel: +86 (21) 52380373

Europe Middle East Africa
Tel: +44 (0)1235 529449

Rest of World
www.tocris.com/distributors
Tel:+1 612 379 2956

Product Name: **BMS 303141** **Catalog No.: 4609** **3**

CAS Number: 943962-47-8

IUPAC Name: 3,5-Dichloro-2-hydroxy-*N*-(4-methoxy[1,1'-biphenyl]-3-yl)-benzenesulfonamide

Description:

BMS 303141 is an ATP citrate lyase (ACL) inhibitor (IC_{50} = 0.13 µM for human recombinant ACL); blocks lipid synthesis (IC_{50} = 8 µM in HepG2 cells). Displays no cytotoxicity up to a concentration of 50 µM. Lowers plasma glucose and triglycerides in a mouse model of hyperlipidemia; reduces cell proliferation in HepG2 and Huh-7 cell lines and in PD-1 deficient lymphomas. Orally bioavailable.

Physical and Chemical Properties:

Batch Molecular Formula: $C_{19}H_{15}Cl_2NO_4S$

Batch Molecular Weight: 424.3

Physical Appearance: Off-white solid

Minimum Purity: ≥98%

Batch Molecular Structure:



Storage: Store at -20°C

Solubility & Usage Info:

DMSO to 10 mM
ethanol to 50 mM

Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. *Unless contradicted by product-specific protocols or instructions, our standard recommendations apply:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

References:

Wartewig *et al* (2023) PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma. Nat.Cancer ***4*** 1508. PMID: 37723306.

Ma *et al* (2009) A novel direct homogeneous assay for ATP citrate lyase. J.Lipid Res. ***50*** 2131. PMID: 19286649.

Li *et al* (2007) 2-hydroxy-*N*-arylbenzenesulfonamides as ATP-citrate lyase inhibitors. Bioorg.Med.Chem.Lett. ***17*** 3208. PMID: 17383874.